SALL2 and breast cancer: Consistently, ERα expression was barely detected in SALL2‐silenced tumors without E2, but strongly expressed in E2‐treated MCF7/control xenografts (Fig 4E), which further supports the hypothesis that silencing SALL2 confers estrogen‐independent tumorigenicity to ER+ breast cancer cells.